secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cocrystal Pharma, Inc. (COCP)
CIK:        0001412486
Form:       8-K
Filed at:   2024-10-31T23:59:59+00:00
Accession:  0001493152-24-043141
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cocrystal Pharma highlights in vitro activity of CC-42344 against avian H5N1, Phase 2a data expected by end of 2024
--------------------------------------------------------------------------------

- CC-42344 showed in vitro activity against avian influenza A (H5N1) PB2 protein; high-resolution crystal structure confirmed binding.
- Phase 2a human challenge study for seasonal influenza A topline safety/tolerability results expected by end of 2024.
- Phase 1 study of pan-viral candidate CDI-988 for noroviruses and coronaviruses; topline data expected late 2024 or early 2025.
- No approved vaccine or antiviral for norovirus; estimated 685M cases and 200K deaths annually worldwide (CDC).
- Preparations underway for US IND application for late-stage study of CC-42344.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1412486/000149315224043141/0001493152-24-043141-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1412486/000149315224043141/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-043141

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer